Royal Bank Of Canada restated their buy rating on shares of Stryker Corporation (NYSE:SYK) in a report issued on Friday morning. Royal Bank Of Canada currently has a $155.00 target price on the medical technology company’s stock.

Several other brokerages also recently commented on SYK. Cowen and Company restated a buy rating and issued a $160.00 price target (up previously from $150.00) on shares of Stryker Corporation in a research report on Sunday, July 30th. BidaskClub upgraded shares of Stryker Corporation from a hold rating to a buy rating in a research report on Thursday, August 17th. Zacks Investment Research downgraded shares of Stryker Corporation from a buy rating to a hold rating in a research report on Thursday, August 17th. Stifel Nicolaus upped their price target on shares of Stryker Corporation from $151.00 to $158.00 and gave the company a buy rating in a research report on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. set a $148.00 price target on shares of Stryker Corporation and gave the company a hold rating in a research report on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company’s stock. Stryker Corporation has an average rating of Hold and a consensus target price of $145.73.

Stryker Corporation (NYSE SYK) traded down 0.20% during trading on Friday, hitting $141.09. The company had a trading volume of 932,343 shares. The company has a market cap of $52.78 billion, a PE ratio of 31.49 and a beta of 0.82. The company’s 50 day moving average price is $144.55 and its 200-day moving average price is $137.64. Stryker Corporation has a 12 month low of $106.48 and a 12 month high of $148.84.

Stryker Corporation (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.51 by $0.02. The business had revenue of $3.01 billion during the quarter, compared to the consensus estimate of $2.98 billion. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The firm’s quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.39 EPS. Equities analysts expect that Stryker Corporation will post $6.47 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Stryker Corporation (SYK) Receives “Buy” Rating from Royal Bank Of Canada” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/stryker-corporation-syk-receives-buy-rating-from-royal-bank-of-canada/1538410.html.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Stockholders of record on Friday, September 29th will be paid a dividend of $0.425 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.70 annualized dividend and a dividend yield of 1.20%. Stryker Corporation’s dividend payout ratio (DPR) is 37.95%.

In related news, insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $146.36, for a total value of $731,800.00. Following the transaction, the insider now directly owns 88,207 shares in the company, valued at approximately $12,909,976.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Graham A. Mclean sold 1,124 shares of the firm’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total transaction of $164,396.24. Following the completion of the transaction, the insider now owns 8,983 shares in the company, valued at $1,313,853.58. The disclosure for this sale can be found here. Insiders sold a total of 32,810 shares of company stock worth $4,754,958 over the last quarter. 7.40% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its position in Stryker Corporation by 2,526.4% in the first quarter. BlackRock Inc. now owns 21,976,771 shares of the medical technology company’s stock worth $2,893,242,000 after buying an additional 21,140,000 shares during the last quarter. Koch Industries Inc. raised its position in Stryker Corporation by 34,120.3% in the second quarter. Koch Industries Inc. now owns 1,260,675 shares of the medical technology company’s stock worth $1,252,000 after buying an additional 1,256,991 shares during the last quarter. Vanguard Group Inc. raised its position in Stryker Corporation by 5.2% in the first quarter. Vanguard Group Inc. now owns 23,421,053 shares of the medical technology company’s stock worth $3,083,382,000 after buying an additional 1,161,688 shares during the last quarter. Janus Henderson Group PLC raised its position in Stryker Corporation by 2,237.8% in the second quarter. Janus Henderson Group PLC now owns 1,019,254 shares of the medical technology company’s stock worth $141,452,000 after buying an additional 975,656 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in Stryker Corporation by 41.9% in the first quarter. PNC Financial Services Group Inc. now owns 1,403,420 shares of the medical technology company’s stock worth $184,759,000 after buying an additional 414,715 shares during the last quarter. Institutional investors and hedge funds own 74.16% of the company’s stock.

About Stryker Corporation

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.